SpringTide Ventures is a venture capital firm dedicated to supporting the world's leading healthcare innovators. Established in 2018, the firm focuses on early-stage investments in digital health, medical devices, life sciences, and tech-enabled care delivery. With offices in Boston, Salt Lake City, and San Francisco, SpringTide Ventures manages over $100 million in assets.

The firm's investment philosophy centers on partnering with entrepreneurs who are positively disrupting healthcare to enhance patient care, improve outcomes, and expand access to quality care. Notable achievements include the acquisition of portfolio company PathologyWatch by Sonic Healthcare for $150 million in January 2024, and the launch of Debut Biotech's skincare product line following a $20 million Series B funding led by L'Oréal. SpringTide Ventures also hosts biannual forums to address key healthcare issues and identify potential solutions.